健民集團(600976.SH):擬認購巢生二期基金的基金份額2000萬元
格隆匯8月16日丨健民集團(600976.SH)公佈,為進一步拓寬公司併購渠道,提升公司資產運作水平,提高資金收益,公司擬作為有限合夥人認購杭州巢生二期創業投資合夥企業(有限合夥)基金份額2000萬元,資金來源於公司自有資金,根據計劃募資規模,預計佔巢生二期基金9.8%的基金份額(具體佔比將以實際募集情況為準)。
杭州巢生二期創業投資合夥企業(有限合夥)(以下簡稱:巢生二期基金)成立於2022年2月28日,基金擬定募資規模為2.04億元,已認繳出資1.24億元;基金管理人為巢生(北京)創業投資管理有限公司;基金主要致力於生物醫藥及生命科學領域的創新項目孵化投資以及早中期項目投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.